# Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female Volunteers

> **NCT02171546** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 42 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Dabigatran etexilate capsules
- **DRUG:** Quinidine sulfate tablets
- **DRUG:** Fexofenadine tablets

## Key facts

- **NCT ID:** NCT02171546
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2008-01
- **Final completion:** —
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02171546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02171546, "Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female Volunteers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02171546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*